ILMN NASDAQ
Illumina, Inc.
1W: +3.2%
1M: +0.4%
3M: +40.5%
YTD: +101.7%
1Y: +171.1%
3Y: +132.4%
5Y: -32.1%
$279.47
+8.43 (+3.11%)
After Hours: $279.54 (+0.07, +0.03%)
Weekly Expected Move ±7.6%
$228
$249
$269
$290
$311
Credit Risk of going bust: lower than 69% of companies Debt: 5.8% of company value Bonds: $101.9M held by 175 funds, 69 bp over Treasuries → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.68 (down 99.4%), Illumina, Inc. would be worth roughly what it owes.
Total debt $2.53B against a stock market value of $40.93B.
Distance to default 7.36 (Merton model): prices to 2026-10-26, balance sheet 2026-06-28, debt counted $1.25B (short-term plus half of long-term), stock volatility 48.3%; Altman Z'' 3.12. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $1.68 (down 99.4%), Illumina, Inc. would be worth roughly what it owes.
Total debt $2.53B against a stock market value of $40.93B.
Distance to default 7.36 (Merton model): prices to 2026-10-26, balance sheet 2026-06-28, debt counted $1.25B (short-term plus half of long-term), stock volatility 48.3%; Altman Z'' 3.12. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
15 relationships12
As Filer
counterparties named
3
As Counterparty
mentioned by others
3
Rel. Types
2021-10-29
Earliest Filing
2026-02-02
Latest Filing
target: 9
partner: 2
acquirer: 1
Counterparties (Filed by ILMN)
12 relationshipsCompanies named in ILMN's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Standard BioTools Inc. | LAB | target | Target of acquisition for aptamer-based and functional proteomics business | 2026-01-30 | View |
| SomaLogic | — | target | Target subsidiary acquired as part of the Standard BioTools transaction | 2026-01-30 | View |
| Sengenics Corporation LLC | — | target | Target subsidiary acquired as part of the Standard BioTools transaction | 2026-01-30 | View |
| Sengenics Corporation Pte Ltd | — | target | Target subsidiary acquired as part of the Standard BioTools transaction | 2026-01-30 | View |
| Standard BioTools Inc. | LAB | acquirer | Target of acquisition for aptamer-based and functional proteomics business | 2025-06-23 | View |
| SomaLogic, Inc. | SLM | target | Acquired by Illumina through Standard BioTools | 2025-06-23 | View |
| Sengenics Corporation LLC | — | target | Acquired by Illumina through Standard BioTools | 2025-06-23 | View |
| Sengenics Corporation Pte Ltd | — | target | Acquired by Illumina through Standard BioTools | 2025-06-23 | View |
| GRAIL, Inc. | GRAL | target | Spin-off from Illumina, Inc. becoming an independent public company | 2024-06-27 | View |
| GRAIL, Inc. | GRAL | partner | Spin-off entity separated from Illumina, Inc. | 2024-06-24 | View |
| GRAIL, LLC | GRAL | partner | Legal entity representing GRAIL, Inc. in separation agreements. | 2024-06-24 | View |
| GRAIL, Inc. | GRAL | target | Target of merger with Illumina, Inc. | 2021-10-29 | View |
Mentioned As Counterparty
3 mentionsOther companies that named ILMN in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| PACB PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | partner | Signatory to the Asset Purchase Agreement alongside Pacific Biosciences of California, Inc. and Illumina Cambridge Limit | 2026-02-02 | View |
| LAB STANDARD BIOTOOLS INC. | target | Acquired all equity interests of SomaLogic, Inc., Sengenics Corporation LLC, and Sengenics Corporation Pte Ltd for up to | 2026-01-30 | View |
| LAB STANDARD BIOTOOLS INC. | target | Acquired all equity interests of SomaLogic, Inc., Sengenics Corporation LLC, and Sengenics Corporation Pte Ltd for up to | 2025-06-23 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-13 | Material Agreement; Financial Obligation; Exhibits | Agreement | View |
| 2026-08-17 | Other Events; Exhibits | View | |
| 2026-08-13 | Material Agreement; Termination of Agreement; Financial Obligation; Exhibits | Agreement | View |
| 2026-08-12 | Other Events; Exhibits | View | |
| 2026-08-07 | Other Events; Exhibits | View | |
| 2026-07-30 | Earnings Release; Exhibits | View | |
| 2026-06-23 | Officer/Director Change | View | |
| 2026-05-26 | Shareholder Vote; Exhibits | View | |
| 2026-04-30 | Earnings Release; Other Events; Exhibits | View | |
| 2026-04-02 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-02-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-30 | Completion of Acquisition or Disposition of Assets; Other Events; Financial Statements and Exhibits | Acquisition | View |
| 2026-01-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-08 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-11-25 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-12 | Other Events; Financial Statements and Exhibits | View | |
| 2025-10-30 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-31 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-23 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-05-23 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR